793 related articles for article (PubMed ID: 26386686)
21. Ulcerative Colitis: Shifting Sands.
D'Haens GRAM; Lindsay JO; Panaccione R; Schreiber S
Drugs R D; 2019 Jun; 19(2):227-234. PubMed ID: 30827006
[TBL] [Abstract][Full Text] [Related]
22. An update on anti-TNF agents in ulcerative colitis.
Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
[TBL] [Abstract][Full Text] [Related]
23. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
Hinojosa Del Val J; Barreiro-de Acosta M
Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
[TBL] [Abstract][Full Text] [Related]
24. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.
Jin Y; Lin Y; Lin LJ; Zheng CQ
World J Gastroenterol; 2015 May; 21(20):6352-60. PubMed ID: 26034371
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Carman N; Mack DR; Benchimol EI
Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
[TBL] [Abstract][Full Text] [Related]
26. Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients.
Thapa SD; Hadid H; Usman M; Imam W; Hassan A; Schairer J; Jafri SM; Kaur N
Dig Dis Sci; 2016 Jan; 61(1):230-7. PubMed ID: 26511478
[TBL] [Abstract][Full Text] [Related]
27. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab.
Dalal RS; Ananthakrishnan AN; Hamilton MJ; Winter RW
Dig Dis Sci; 2021 Mar; 66(3):733-737. PubMed ID: 33569666
[No Abstract] [Full Text] [Related]
28. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?
D'Amico F; Danese S; Peyrin-Biroulet L
Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748
[No Abstract] [Full Text] [Related]
29. An Update on Surveillance in Ulcerative Colitis.
Limdi JK; Farraye FA
Curr Gastroenterol Rep; 2018 Mar; 20(2):7. PubMed ID: 29516293
[TBL] [Abstract][Full Text] [Related]
30. [Management of diagnosis and treatment in ulcerative colitis].
Klotz C; Barret M; Dhooge M; Oudjit A; Chaussade S; Coriat R; Abitbol V
Presse Med; 2015 Feb; 44(2):144-9. PubMed ID: 25534469
[TBL] [Abstract][Full Text] [Related]
31. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
32. Ulcerative Colitis.
Sonnenberg E; Siegmund B
Digestion; 2016; 94(4):181-185. PubMed ID: 27931025
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.
Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M
Rev Esp Enferm Dig; 2017 Sep; 109(9):659-662. PubMed ID: 28724302
[TBL] [Abstract][Full Text] [Related]
34. The biologics of ulcerative colitis.
Macaluso FS; Renna S; Orlando A; Cottone M
Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557
[TBL] [Abstract][Full Text] [Related]
35. Overview of biological therapy in ulcerative colitis: current and future directions.
Furfaro F; Bezzio C; Ardizzone S; Massari A; de Franchis R; Maconi G
J Gastrointestin Liver Dis; 2015 Jun; 24(2):203-13. PubMed ID: 26114181
[TBL] [Abstract][Full Text] [Related]
36. Self-reported frequency and severity of disease flares, disease perception, and flare treatments in patients with ulcerative colitis: results of a national internet-based survey.
Bolge SC; Waters H; Piech CT
Clin Ther; 2010 Feb; 32(2):238-45. PubMed ID: 20206781
[TBL] [Abstract][Full Text] [Related]
37. Golimumab for moderate to severe ulcerative colitis.
Strik AS; Berends SE; Mathôt RA; D'Haens GR; Löwenberg M
Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):401-406. PubMed ID: 28276288
[TBL] [Abstract][Full Text] [Related]
38. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis.
Rosen MJ; Minar P; Vinks AA
Aliment Pharmacol Ther; 2015 Jun; 41(11):1094-103. PubMed ID: 25809869
[TBL] [Abstract][Full Text] [Related]
39. Should we use vedolizumab as mono or combo therapy in ulcerative colitis?
Hedin C; Halfvarson J
Best Pract Res Clin Gastroenterol; 2018; 32-33():27-34. PubMed ID: 30060935
[TBL] [Abstract][Full Text] [Related]
40. Biological therapy for ulcerative colitis: an update.
Seo GS; Chae SC
World J Gastroenterol; 2014 Oct; 20(37):13234-8. PubMed ID: 25309060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]